Life Sciences Ontario’s Post

Unlock Exceptional Growth at #Pharma_Europe 2024 ! Immerse yourself in unmatched growth and #innovation at Pharma Europe 2024, happening on July 25-26 in Frankfurt, Germany. This leading event is your gateway to #professional development and #industry advancement. Don’t miss out on this #chance to elevate your #career and expertise. Why Present at Pharma Europe 2024? ·        Expand Your Knowledge Base ·        Enhance Your Skillset ·        Boost Your Professional Profile ·        Connect with a Global Community #PharmaEurope2024 #CallForProposals #IndustryExperts #ProfessionalDevelopment #NetworkingOpportunities #SubmitYourProposal #SuccessStories  

Another great Saturday is approaching ! This week we have Bárbara Aranda da Silva talking about key important Market Access activities for a successful and sustainable post-launch phase of a product. Do you want to know more about this course ? Reach out to me, Alexandre Calaça Baptista Beatriz Silva Lima or Helder Mota Filipe #heor #MarketAccess #RWE #reimbursement #FFUL #onlinecourse

Last week, USP welcomed a delegation of senior executives and leaders from Mexico's Asociación Mexicana de Laboratorios Farmacéuticos (AMELAF) in Rockville, MD. This meeting marks an important milestone in USP's ongoing engagement with industry leaders in Mexico, building upon AMELAF joining USP as a Convention member last year. The highlight of the meeting was the signing of a memorandum of understanding between AMELAF and USP, starting a new chapter of collaboration. • USP and AMELAF will establish a consistent channel for sharing vital insights on emerging quality challenges and best practices in effectively applying quality standards. • The organizations will collaborate on targeted training programs and knowledge-sharing activities aimed at strengthening quality assurance systems and standard-setting. • We will work together to advance long-term strategies promoting sustainable access to quality-assured medicines. By combining USP and AMELAF's expertise in standards-setting, shared goals, and local and global networks, the collaboration aims to accelerate progress toward delivering quality medicines to patients in Mexico and globally. Stay tuned for updates on this collaboration! Juan de Villafranca

I will be at the World Evidence, Pricing and Access Congress in Amsterdam today and tomorrow. If you want are here and would like to have a chat about authorisation, pricing and market access of therapies and other health technologies in the Middle East and Africa, drop me a message. #EPAConf #EvidencePricingandAccess #MarketAccess #PricingandReimbursement

👉 Join us as industry experts explore the dynamic and evolving landscape of the BioPharmaChem sector on a global scale. From rising costs to geopolitical instability, innovation strategies to M&A trends, and regulatory shifts to demographic changes, our session will delve into key trends shaping the industry's trajectory. You'll hear from speakers about how they are adapting their business models and what this means for Ireland as a location of choice for sustainable development and investment. Gain insights into emerging markets, transformative therapies and the impact of geopolitical factors on innovation. Don't miss this opportunity to navigate the shifting landscape of the BioPharmaChem. sector. Meet the panel: ⚡ Chair: Alison Comyn, Journalist, Broadcaster and News Anchor ⚡ Joyce Fitzharris, President, SK pharmteco, Small Molecule Europe Division, BPCI Vice Chair. ⚡ Dana Daneshvari, VP of Manufacturing and General Manager, The Janssen Pharmaceutical Companies of Johnson & Johnson ⚡ Rory Mullen, Head of BioPharma, IDA Ireland ⚡ Aine Brassill, Partner, PwC Taking place on the 23 May, Fota Island, Cork, register at www.bpcimpact.ie Thank you to our sponsors: GOLD: CAMIDA and SILVER: BioPharmaChem Skillnet, IDA Ireland, Innopharma Technical Services, PMTC, PwC, Laboratory Apprenticeship , Micro-Bio #BioPharmaChem #GlobalTrends #Innovation #Healthcare #Strategy #Leadership #Regulation #M&A

Let's look back to the remarkable achievements of the Prix Galien 2023 USA winners. 🏆 Let's take a trip down memory lane and remember the extraordinary innovations that continue to shape the landscape of healthcare. To Bristol Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, CSL / uniQure, Guardant Health, Medable, Inc, Villgro Africa, GrayMatters Health, and Volta Medical: Your contributions have left an indelible mark on the world of healthcare. Your vision, dedication, and unwavering commitment to excellence have inspired us all. As we reflect on this special moment, we're reminded of the boundless potential of human ingenuity and the power of innovation to transform lives. Here's to the enduring legacy of the Prix Galien winners and the hope they continue to bring to patients worldwide. Join us in honoring these visionary leaders and innovators as we look back on a year filled with groundbreaking achievements. #throwbackthursday #PrixGalien #healthcareinnovation #medicalresearch #pharmaceuticalindustry #biotechnology

Delighted to share my experience from Winter Wave, Wave 20 organized by PharmaSchemes. Grateful for the opportunity to delve into various topics including: - Cosmetics: Exploring the latest trends and innovations in the cosmetic industry led by Dr. Bassam Barakat. - Industrial Aspects: Understanding the industrial processes and operations within the pharmaceutical sector facilitated by Dr. muhammad hosni. - OTC Drugs and Patient Counseling: Learning about over-the-counter medications and their role in healthcare led by Dr. Waseem Maged. - Pharmaceutical Compounding: Deepening my knowledge of customized medication formulations under the guidance of Dr. huda ezzat. - Soft Skills and Self-Awareness: Nurturing essential soft skills and fostering self-awareness for holistic growth guided by Dr. Waseem Maged. - Traveling Abroad: Discovering the global landscape of pharmaceutical practices led by Dr. Ahmed Kabsha - Self-Branding and LinkedIn: Enhancing personal branding strategies and leveraging LinkedIn for professional growth. - Different Pharmaceutical Career Pathways: Exploring diverse career options within the pharmaceutical industry by Dr. Mohamed Saied. Grateful for the 20 hours of immersive learning across 8 insightful sessions. This experience has been truly invaluable for my professional development. #winterwave #pharmaschemes #otcdrugs #careerpathways #selfbranding #traveling #cosmetics #indusrialaspects #pharmaceuticalcompounding #continuouslearning

Exciting news! Our first member offering a 'member to member' discount! Also our first consulting firm member 😀 Welcome to Spot-on Pharma Consulting who will be offering a 20% discount on hourly rate when engaging Erik Steffensen 🤗 To find out more about membership visit our website https://lnkd.in/dHBx_F5K ABOUT Spot-on Pharma Consulting Spot-on Pharma Consulting has expert knowledge within development and manufacturing of ATMPs, including CMC Development, GMP Manufacturing and Quality Assurance. We can guide you in the early phases of development, when speed and proof of concept are in focus, and in clinical phase III and market phases where process robustness and scalability are very important. An experienced partner with phase appropriate development is key to your success. Manufacturing batches for clinical trials and the market must be done according to the rules for GMP. As a manufacturer/sponsor you need to control the whole supply chain, from sourcing of raw materials to shipment of products to clinical sites or hospitals. Even when outsourcing a sponsor must ensure all contracts are in place and oversight is performed. The founder of the company Erik Steffensen is the co-author of guide "ATMPs - Development and Manufacturing of Allogeneic Cell Therapies" published by the International Society of Pharmaceutical Engineering (ISPE) in 2024.

EY is actively engaging with governments in acing the GCC footprint in India.

I was delighted to join my counterparts at recent committee meetings of EFPIA - European Federation of Pharmaceutical Industries and Associations. EFPIA provides a vital opportunity to collaborate and focus on the key issues of today that impact our industry and the patients we serve. These most recent discussions reinforced the importance of timely and equitable access to medicines across Europe. To borrow Pfizer’s purpose statement – Breakthroughs that Change Patients’ Lives – we can produce the Breakthroughs, but we won’t change patients’ lives (and we’re targeting 1 billion by 2027!) if we can’t get these innovative products into patients’ hands. Medicines are an investment in peoples’ futures and the foundation stone for societal and economic growth. Research in Ireland found every Euro invested in medicines saves society €3.80 in additional spending such as wider healthcare costs and lost productivity.* Investment in medicines and vaccines is an investment in our people, reducing health inequalities and levelling up outcomes. But this premise is under threat by increasing measures at a European and country level to consider medical innovation merely as a cost to contain. No other health innovation is held on pause and scrutinized in the way we scrutinize medicines. But denying or delaying treatment on a prediction that it will be too successful and thus too high a cost is the antithesis of patient centricity and can create deeper problems for future health management. As an industry, we want to see European citizens benefit from the innovative medicines we develop. And investment – driven by using the current treatments and building future treatments through R&D – is what keeps the wheels of innovation turning. But investment needs the right predictable environmental conditions to thrive. Europe’s global competitiveness and attractiveness for R&D investment is under pressure. Over the last 25 years, treatments emanating from Europe have dropped by 30%.** A competitive environment, powered by strong incentives (notably intellectual property) is critical to pull the investment back up, generate future growth and get the medicines into the hands of those who need them most.  #WeWontRest #healthandwealth   * WifOR Institute. Value of medicines in Ireland. Published March 2021 ** EU Competitiveness: Mind the gap between rhetoric and reality (efpia.eu)